QWO is the first and only FDA-approved non-surgical injectable for the treatment of moderate to severe cellulite in the buttock of adult women.
Treatment consists of three QWO treatments, one every 3 weeks. Injections take 10 minutes or less. In clinical trials, no post-treatment downtime was required.
There are 3 primary structural factors associated with the appearance of cellulite.:
- Fibrous septae that tether the dermis to the deep fascia
- Fat lobules that are segmented by fibrous septae and push against the skin
- The dermis becoming thinner
QWO is made from enzymes called collagenases. These enzymes are thought to target the structural causes under the skin, where cellulite starts. It's thought that QWO works by releasing fibrous bands, redistributing fat cells, and stimulating the growth of new collagen. The best description of the treatment process would be QWO causes Enzymatic Subcision and Remodeling (ESR). QWO enzymatically subcizes the fibrous septae, reorganizes fat lobules, and initiates neocollagenesis and helps thicken the dermis. Desired results may be achieved in 28 days following the 3rd treatment. No post treatment downtime is required.
Bruising at the injection site is expected which could last 3 weeks with residual discoloration for a couple of months. Each subsequent treatment will cause less bruising. The injection causes a breakdown of the small superficial blood vessels that surround the collagen that is being released. Other potential side effects are pain, areas of hardness, itching, redness, swelling and warmth at the treatment area.
Endo Aesthetics conducted the largest clinical trials in the history of cellulite investigation to help determine the safety and efficacy of QWO. All skin types and ethnicities were studied.